Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...

Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...

Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

The publication will be followed by an investor conference call and webcast on Tuesday, Nov Cellectis SA (CLLS) has released an update ... July 25, 2024 (GLOBE NE Regenxbio (RGNX) witnessed a jump in ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

The attack came just days after President Biden gave Ukraine permission to use the weapons to strike targets inside Russia. By Marc Santora and Eric Schmitt The envoy, Amos Hochstein, said an ...

Trump Defies the #MeToo Movement With Cabinet Picks Facing Accusations Donald Trump, who was found liable for sexual abuse last year, appears determined to force a fight over the role of such ...

Stewart-Haas' sad demise belies its legacy of unlikely success (October 31, 2024, 7:00 PM ET) ...